Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced participation in two key healthcare conferences in May 2021. The first is the RBC Capital Markets Global Healthcare Conference on May 18 at 1:20 PM EDT, featuring CFO Hans van Houte and SVP Robert J. Brown, M.D. The second is the UBS Global Healthcare Virtual Conference on May 25 at 4:00 PM EDT, with CEO Arthur T. Sands, M.D., Ph.D. Both events will be webcast live, accessible via the Nurix website, with recordings available for 30 days post-event.

SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of Nurix management team will participate in the following conferences in May:

• RBC Capital Markets Global Healthcare Conference
  Tuesday, May 18th, at 1:20 PM EDT
  Fireside chat: Hans van Houte, Nurix’s chief financial officer and Robert J. Brown, M.D., senior vice president of clinical development
  
• UBS Global Healthcare Virtual Conference
  Tuesday, May 25^th, at 4:00 PM EDT
  Fireside chat: Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer

The discussions will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

Contacts:

Investors:	Media:
Jason Kantor, Ph.D.	Elizabeth Wolffe, Ph.D.
Nurix Therapeutics, Inc.	Wheelhouse Life Science Advisors
jkantor@nurixtx.com	lwolffe@wheelhouselsa.com

 

FAQ

What are the dates for the Nurix Therapeutics healthcare conferences?

Nurix Therapeutics will participate in the RBC Capital Markets Global Healthcare Conference on May 18, 2021, and the UBS Global Healthcare Virtual Conference on May 25, 2021.

Who will represent Nurix Therapeutics at the RBC conference?

At the RBC Capital Markets Global Healthcare Conference, CFO Hans van Houte and SVP Robert J. Brown, M.D. will represent Nurix Therapeutics.

What time is the UBS Global Healthcare Virtual Conference?

The UBS Global Healthcare Virtual Conference will take place on May 25, 2021, at 4:00 PM EDT.

Where can I watch the Nurix Therapeutics conference webcasts?

The webcasts for Nurix Therapeutics conferences can be accessed through the Investors section of the Nurix website, with archived copies available for about 30 days after the events.

What is Nurix Therapeutics focusing on in their drug development?

Nurix Therapeutics is focused on developing targeted protein modulation drugs for cancer and other diseases, leveraging their expertise in E3 ligases.